Ultra Nasdaq Biotechnology Proshares (BIB) 166.99

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 1:34 PM

Ultra Nasdaq Biotechnology Proshares (BIB) 166.99 $BIB

Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 419.87 (+6.52), BBC: 33.77 (+0.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14), AMGN: 162.01 (+7.75)

12.6% Return Seen to Date on SmarTrend ProShares Ultra Nasdaq Biotechnology ETF Call (BIB)
Comtex SmarTrend(R) - Fri Mar 13, 5:13PM CDT
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on February 17th, 2015 at $142.82. In approximately 3 weeks, ProShares Ultra Nasdaq Biotechnology ETF has returned 12.64% as of today's recent price of $160.87.
BIB: 166.99 (+6.12)

3 Biotech ETFs Crushing The Market In 2015
Zacks Funds - Seeking Alpha - Fri Mar 13, 3:16PM CDT
As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a number of companies in this sector lately, turning...
BBC: 33.77 (+0.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14)

3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 419.87 (+6.52), BBC: 33.77 (+0.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14), IBB: 351.73 (+6.40), AMGN: 162.01 (+7.75)

Biotech selling off early
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST

BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

Ugly day for biotech
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 1:03PM CST

BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

Biotech off to a good start on first trading day of 2015
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:57AM CST

BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 83.58 (+2.21), GILD: 100.91 (+1.30), FBT: 123.19 (+2.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14), IBB: 351.73 (+6.40), BBH: 133.25 (+2.94), ABBV: 58.91 (+0.91)

Look for Shares of ProShares Ultra Nasdaq Biotechnology ETF to Potentially Rebound after Yesterday's 9.20% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 5:13PM CST
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $116.34 to a high of $131.99. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $128.10 on volume of 948,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIB: 166.99 (+6.12)

Money flowing out of biotech today
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:40AM CST

BIS: 33.19 (-1.36), ESRX: 83.58 (+2.21), GILD: 100.91 (+1.30), BIB: 166.99 (+6.12), IBB: 351.73 (+6.40), ABBV: 58.91 (+0.91)

ProShares Ultra Nasdaq Biotechnology ETF Has Returned 22.8% Since SmarTrend Recommendation (BIB)
Comtex SmarTrend(R) - Mon Dec 15, 9:19AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 months, ProShares Ultra Nasdaq Biotechnology ETF has returned 22.84% as of today's recent price of $128.68.
BIB: 166.99 (+6.12)

25.1% Return Seen to Date on SmarTrend ProShares Ultra Nasdaq Biotechnology ETF Call (BIB)
Comtex SmarTrend(R) - Fri Dec 05, 4:55PM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 25.05% as of today's recent price of $131.00.
BIB: 166.99 (+6.12)

Shares of BIB Up 23.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 28, 11:03AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 1 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 23.28% as of today's recent price of $129.14.
BIB: 166.99 (+6.12)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 7.71 (+0.36), BIB: 166.99 (+6.12), INCY: 90.12 (+0.81), PFE: 34.45 (+0.45), IBB: 351.73 (+6.40), DRGS: 60.08 (+1.38), BIND: 5.09 (-0.02), BMY: 67.85 (+0.98), GSK: 46.93 (+0.56), ONTY: 1.74 (-0.02), ECYT: 6.13 (-0.18), BIS: 33.19 (-1.36), CLVS: 81.11 (+3.13), AZN: 68.87 (+1.52), MRK: 57.08 (+0.88), ARIA: 8.66 (+0.18), IRY: 51.54 (+0.64), IXJ: 107.61 (+1.81), FPRX: 25.50 (-0.39)

UniQure sets price record with Glybera
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:33PM CST

BIS: 33.19 (-1.36), QURE: 24.99 (-0.26), BIB: 166.99 (+6.12), ALXN: 178.81 (+1.92), IBB: 351.73 (+6.40)

China mulling eliminating drug price controls
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 6:17AM CST

EWH: 21.15 (+0.18), PEK: 48.23 (+1.94), CNXT: 38.81 (+1.74), KBA: 48.89 (+1.82), BIB: 166.99 (+6.12), CQQQ: 36.60 (+0.45), IBB: 351.73 (+6.40), DRGS: 60.08 (+1.38), CHXF: 51.70 (+0.09), YINN: 36.25 (+1.85), FXP: 39.90 (-1.46), EWHS: 26.52 (+0.48), PGJ: 27.30 (-0.01), FCA: 22.86 (+0.11), YAO: 27.77 (+0.55), FCHI: 52.16 (+0.46), ASHR: 38.18 (+1.52), ASHS: 43.39 (+1.83), GXC: 80.27 (+1.12), FXI: 42.25 (+0.76), XPP: 70.65 (+2.47), KWEB: 31.56 (-0.05), ECNS: 45.38 (+0.36), TAO: 20.62 (+0.02), CHNA: 37.48 (+1.53), QQQC: 21.20 (+0.17), CHIX: 15.41 (+0.25), KFYP: 64.07 (unch), HAO: 25.19 (+0.08), MCHI: 51.78 (+0.84), CHIM: 14.67 (-0.47), YANG: 10.28 (-0.59), BIS: 33.19 (-1.36), CHIQ: 12.56 (+0.02), CHIE: 12.64 (-0.09), FHK: 40.65 (+0.32), CHII: 13.61 (+0.20), YXI: 28.04 (-0.22), CN: 36.22 (+1.17)

Drug makers face pushback on pricey meds
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 7:18AM CST

ABT: 47.70 (+0.82), BIIB: 419.87 (+6.52), BIB: 166.99 (+6.12), PFE: 34.45 (+0.45), AMGN: 162.01 (+7.75), IBB: 351.73 (+6.40), LLY: 71.11 (+1.22), DRGS: 60.08 (+1.38), GSK: 46.93 (+0.56), BMY: 67.85 (+0.98), CELG: 120.25 (+2.52), JNJ: 100.61 (+1.40), ESRX: 83.55 (+2.18), BIS: 33.19 (-1.36), MRK: 57.08 (+0.88), AZN: 68.87 (+1.52), CVS: 104.20 (+0.94), ABBV: 58.91 (+0.91), SNY: 48.71 (+1.64), IRY: 51.54 (+0.64), IXJ: 107.61 (+1.81), NVS: 97.98 (+0.94)

Histogenics on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 3:30PM CST

IPO: 24.08 (+0.23), BIS: 33.19 (-1.36), BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST

IPO: 24.08 (+0.23), BIS: 33.19 (-1.36), BIB: 166.99 (+6.12), CNDO: 2.92 (-0.05), IBB: 351.73 (+6.40), DRGS: 60.08 (+1.38), IXJ: 107.61 (+1.81), IRY: 51.54 (+0.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

High-Grade Copper Spurs Optimism for PolarX in Alaska

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...